DEINOVE Strengthens Its Position in the United States

Regulatory News :

DEINOVE (Paris:ALDEI) (Alternext Paris: ALDEI), a biotech company developing innovative processes for producing biofuels and bio-based chemicals by using Deinococcus bacteria as host strains, today announced that its patent, "High-performance metabolic bacteria¹", has been granted in the United States. This patent covers the biofuel production process from cellulosic or hemicellulosic material - biomass components - by a consolidated bioprocess of degradation and fermentation based on Deinococcus bacteria. This issuance is a recognition of the innovative nature of the DEINOL process in a leading country and participates in the proactive policy of protecting its intellectual property worldwide. Since its inception, DEINOVE has submitted more than 180 international patent applications divided into 17 families, leading to a highly valuable strategic asset.

This month, DEINOVE was admitted to the powerful American organization BIO² in the "Industrial & Environmental" section. As the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations, BIO advocates for its members, and works towards enriching the industry with networking, partnering and education opportunities. BIO organises annual international conferences that have become references in the field.

The United States is a major market for DEINOVE. It is the world's largest ethanol producer with 51 billion litres produced in 2013 against 40.7 billion litres in Brazil and only 6.7 billion litres in Europe³. The major ethanol producers are located in the United States and are actively engaged in the development of second-generation ethanol production processes (2G). Over the past two years, at least eight 2G production units have opened up in the country with an annual capacity of more than 500 million litres.

Emmanuel Petiot, CEO of DEINOVE, said: "With this US patent release, we confirm our competitive advantages and strengthen our ability to forge partnerships with US industry groups, as we did last year with the American derisking hub MBI. This patent supports the efforts we have undertaken in the United States and provides us with credibility. At the same time, our BIO membership will open up more opportunities for cooperation. We are confident in our technology development prospects in the world's largest market".

About DEINOVE

DEINOVE (Alternext Paris: ALDEI) is ushering in a new era of green chemistry by designing and developing new standards of production based on bacteria of untapped potential: the Deinococci. Taking advantage of the bacteria’s unique genetic properties and unusual robustness, DEINOVE optimizes natural fermentation and metabolic capabilities of these bacterial "micro-factories" to produce high value-added products from non-food biomass. The Company’s primary markets are 2nd-generation biofuels (DEINOL) and bio-based chemicals (DEINOCHEM). On these markets, the Company offers its technology to industrial partners globally.
Listed on NYSE Alternext since April 2010, DEINOVE was founded by Dr. Philippe Pouletty, General Partner of TRUFFLE CAPITAL, and Pr. Miroslav Radman, of the Faculty of Medicine of Paris Descartes University. The company employs over 40 people in its new offices and laboratories located in Montpellier, France.

More information at www.deinove.com

¹ PCT publication number: WO2010/130812
² https://www.bio.org/category/industrial-environmental
³ Source: State of the industry report 2014 —ePURE